within Pharmacolibrary.Drugs.ATC.N;

model N03AX25
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.88,
    Cl             = 2.9500000000000002e-05,
    adminDuration  = 600,
    adminMass      = 200 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.040100000000000004,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.001,
    Tlag           = 0
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N03AX25</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Cenobamate is an antiepileptic drug (AED) used for the treatment of partial-onset seizures in adults. It is approved in the United States and Europe for this indication, typically as adjunctive therapy in patients with epilepsy.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after single and multiple oral doses.</p><h4>References</h4><ol><li><p>Vernillet, L, et al., &amp; Kamin, M (2020). Pharmacokinetics of Cenobamate: Results From Single and Multiple Oral Ascending-Dose Studies in Healthy Subjects. <i>Clinical pharmacology in drug development</i> 9(4) 428–443. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.769&quot;>10.1002/cpdd.769</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32087001/&quot;>https://pubmed.ncbi.nlm.nih.gov/32087001</a></p></li><li><p>Barbieri, MA, et al., &amp; Franco, V (2023). Cenobamate: A Review of its Pharmacological Properties, Clinical Efficacy and Tolerability Profile in the Treatment of Epilepsy. <i>CNS &amp; neurological disorders drug targets</i> 22(3) 394–403. DOI:<a href=&quot;https://doi.org/10.2174/1871527321666220113110044&quot;>10.2174/1871527321666220113110044</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35049441/&quot;>https://pubmed.ncbi.nlm.nih.gov/35049441</a></p></li><li><p> (2024). Comparison Table: Some oral antiseizure medications. <i>The Medical letter on drugs and therapeutics</i> 66(1708) e133–e140. DOI:<a href=&quot;https://doi.org/10.58347/tml.2024.1708b&quot;>10.58347/tml.2024.1708b</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39073881/&quot;>https://pubmed.ncbi.nlm.nih.gov/39073881</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N03AX25;
